Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449091 | 0.93 | STING1 (1.00) | STING1IRF3 | |
| SCHEMBL22135280 | 0.91 | STING1 (0.89) | STING1IRF3 | |
| SCHEMBL22135231 | 0.91 | STING1 (0.89) | STING1IRF3 | |
| SCHEMBL22135012 | 0.90 | STING1 (1.00) | STING1IRF3 | |
| SCHEMBL22135219 | 0.90 | STING1 (0.90) | STING1IRF3 | |
| SCHEMBL22135211 | 0.89 | STING1 (1.00) | STING1 | |
| SCHEMBL22135303 | 0.88 | STING1 (0.87) | STING1IRF3 | |
| SCHEMBL22135216 | 0.88 | STING1 (0.91) | STING1 | |
| SCHEMBL21648072 | 0.87 | STING1 (0.89) | STING1IRF3 | |
| SCHEMBL22135076 | 0.87 | STING1 (1.00) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210968-A1 | RIBONUCLEOPROTEIN APPROACH TO BOOST THE STING SIGNALING FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-07-06 | — | — | US | disclosed |
| US-20230210968-A1 | RIBONUCLEOPROTEIN APPROACH TO BOOST THE STING SIGNALING FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-07-06 | — | — | US | disclosed |
| CN-112279835-B | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-112279835-A | Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2021-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210968-A1 | RIBONUCLEOPROTEIN APPROACH TO BOOST THE STING SIGNALING FOR CANCER IMMUNOTHERAPY | STING1, IRF3, MAVS | STING1 1/4885IRF3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.